The HER4-YAP1 axis promotes trastuzumab resistance in HER2-positive gastric cancer by inducing epithelial and mesenchymal transition

Trastuzumab is the only target to be approved as the first-line treatment of HER2 positive metastatic gastric cancer, but ubiquitous resistance decreases its therapeutic benefit. In this study, we found HER4, phosphorylation HER4 (p-HER4) and the mesenchymal marker Vimentin increased in trastuzumab-...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Jiaolong, Li, Fengping, Yao, Xingxing, Mou, Tingyu, Xu, Zhijun, Han, Zheng, Chen, Siyu, Li, Wende, Yu, Jiang, Qi, Xiaolong, Liu, Hao, Li, Guoxin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5978807/
https://www.ncbi.nlm.nih.gov/pubmed/29535422
http://dx.doi.org/10.1038/s41388-018-0204-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5978807/
https://www.ncbi.nlm.nih.gov/pubmed/29535422
http://dx.doi.org/10.1038/s41388-018-0204-5

Ejemplares similares